Immunohematology Market – Global Industry Analysis Report, Share, Growth, Price Trends and Forecast, 2017 – 2024: Global Market Insights Inc. The global Immunohematology Market share report provides numbers for applications and regional segments of the industry covering historical as well as forecast data for decision makers. Immunohematology Market size is anticipated to experience significant growth over the forecast period. Increased number of trauma cases and rise in the number of trauma care centers drives the Immunohematology market size. As per CDC, trauma is major cause of death for American people between 1 to 46 years old, and it is accounts for 30% of deaths in U.S. About 2.3 million hospital admissions and 41 million emergency visits registers each year across the U.S. Moreover, burns also accelerates immunohematology market over forecast timeline. In accordance with CDC, 4,50,000 burn injuries require medical care per year, 40,000 hospitalizations, and 3,400 deaths registered each year.
The reagents used in immunohematology segment accounts for majority of market share due to novel products and an increased number of blood banks procuring these reagents. Increased adoption of advanced technologies in immunohematology analyzers enables to offers robust opportunities for the market players. For instance, Ortho Clinical Diagnostics launched the ORTHO VISION, a fully automated system for laboratories to test the blood to be used in the transfusion medicine. Hospital segment is expected to contribute significantly owing to rise in the number of emergency cases due to accidents and trauma cases. In addition, the adoption rate for consumables, medical products are high in case of hospitals as they collaborate with government organizations, suppliers, as well as reimbursement authorities. U.S. market size is expected to witness lucrative opportunities from 2017 to 2024, due to increased prevalence rate of various hematological disorders in the country. According to CDC, approximately 9,00, 000 patients affected with venous thromboembolism each year in the U.S. about 33% of people with venous thromboembolism will have recurrence within 10 years. About 5% to 8% of U.S population has genetic risk factors for thrombosis. 1|Page